01952

21.7605.23%
YL

Yongqing Luo

CEO & Executive Director

Mr. Yongqing Luo, also known as Rogers, is CEO & Executive Director of Everest Medicines Limited from September 19, 2022. He was President and General Manager of Greater China at Brii Biosciences Limited and served as its Executive Director until September 15, 2022. He also served as the Chief Executive Officer of TSB Therapeutics until September 15, 2022, a joint venture established by Brii Bio, Tsinghua University and the 3rd Peoples Hospital of Shenzhen. He had been Vice President and General Manager of Commercial Operations in China at Gilead Sciences Inc. from September 2016 to September 2020, during which he built Gilead Sciences, Inc. presence in China from beginning as an early Employee in China. He led the development, regulatory review and launch of eight innovative products, gaining rapid access across China. He also led the team and established a unique business model encompassing science, commercialization, and patient access. He was the Vice President of Shanghai Roche Pharmaceuticals Ltd., and responsible for pioneering novel strategies for patient access to oncology therapies from August 2012 to August 2016. He was the Head of Great China at Beijing Novartis Pharma Co., Ltd. (Novartis) from June 2009 to August 2012, and the associate brand Director of the Novartis global Headquarter in Switzerland from September 2007 to June 2009. Mr. Luo received his medical education from Xiangya School of Medicine, Central-South University, in China and graduated in July 1992, and then served for years as a surgeon at St. Lukes Hospital, Shanghai, from July 1992 to July 1995. He obtained an Executive Master of Business Administration from China Europe International Business School in China in September 2006.

Positions